Abstract
Wastewater testing has emerged as an effective, widely used tool for population-level SARS-CoV-2 surveillance. Such efforts have primarily been implemented at the wastewater treatment plants (WWTPs), providing data for large resident populations but hindering the ability to implement targeted interventions or follow-ups. Conversely, building-level wastewater data exhibits increased variability due to rapid daily population dynamics but allows for targeted follow-up interventions or mitigation efforts. Here, we implemented a three-site wastewater sampling strategy on our university-affiliated medical campus from May 2021 to March 2024, comprised of two distinct hospital quadrants and a primarily research laboratory and classroom building. We first addressed several limitations in implementing hospital-level wastewater surveillance by optimizing sampling frequency and laboratory techniques. We subsequently improved our ability to model SARS-CoV-2 case counts using wastewater data by performing sensitivity analyses on viral shedding assumptions and testing the utility of internal normalization factors for population size. Our unique infrastructure allowed us to detect intra-hospital dynamics of SARS-CoV-2 prevalence and diversity and confirmed that direct sequencing of wastewater was able to capture corresponding clinical viral diversity. In contrast, research building wastewater sampling showed that for most non-residential settings, despite low overall viral loads, a threshold approach can still be used to identify peaks in cases or transmission amongst the general population. Our study expands on current wastewater surveillance practices by examining the utility of and best practices for upstream and particularly hospital settings, enabling the use of non-municipal, medium-scale wastewater testing to inform efforts for reducing the burden of COVID-19.
Importance Since the onset of the COVID-19 pandemic, wastewater surveillance has been increasingly implemented to track the spread of SARS-CoV-2. Most wastewater testing across the United States occurs at municipal wastewater treatment plants. Yet, this testing method could also be beneficial at non-municipal and non-residential sites, including hospitals, where wastewater data for SARS-CoV-2 signals and viral diversity could directly impact hospital practices to control its spread. We analyzed both hospital and non-residential research building wastewater over a three-year period to establish optimized methods for collecting and interpreting wastewater data at sites upstream of treatment plants. We found that even within a single hospital building, wastewater testing in different locations showed distinct signatures over time, which corresponded with data from patients hospitalized in those locations. This study provides a framework for the use of wastewater viral surveillance upstream of municipal treatment plants to enable targeted interventions to limit the spread of SARS-CoV-2.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the National Institute on Drug Abuse (NIDA U01DA053949 to ACU and MKA) and the National Institute of Allergy and Infectious Diseases (NIAID K99AI163348 to MKA).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of Columbia University Irving Medical Center gave ethical approval for this work (Protocol No. IRB-AAAU1682)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.